VBI Vaccines Inc., a biopharmaceutical company based in Cambridge, Massachusetts, is making strides in the development of vaccines to combat immuno-oncology and infectious diseases. Among its offerings is Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company is also working on VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection, and VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, currently in Phase I/IIa clinical study to treat solid tumors. In addition, VBI Vaccines Inc. has completed Phase I clinical trials of VBI-1501, a prophylactic cytomegalovirus vaccine candidate and is continuing its preclinical trial of VBI-2501 in order to treat the Zika virus. The company has been working on several coronavirus vaccine candidates, including VBI-2902, VBI-2901, and VBI-2905. VBI Vaccines Inc. has also entered into collaboration and license agreements with Brii Biosciences Limited, GlaxoSmithKline Biologicals S.A., and the National Research Council of Canada to create a pan-coronavirus vaccine candidate. This candidate could potentially target COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. Additionally, the company is working with the Coalition for Epidemic Preparedness Innovations to advance vaccine candidates that can address COVID-19 variants. Formerly known as SciVac Therapeutics Inc., VBI Vaccines Inc. changed its name in May 2016. The company's impressive efforts in the world of biopharmaceuticals are worth watching.
VBI Vaccines, Inc.'s ticker is VBIV
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at VBI Vaccines, Inc.
It is https://www.vbivaccines.com/
VBI Vaccines, Inc. is in the Healthcare sector
VBI Vaccines, Inc. is in the Biotechnology industry
The following five companies are VBI Vaccines, Inc.'s industry peers: